Connect with us

Business

FDA approves Roche’s new spinal muscular atrophy drug – MarketWatch

Published

on

post featured image

Roche Holding AG
ROG,
-0.27%
said Friday that the Food and Drug Administration had approved Evrysdi, a treatment for spinal muscular atrophy in adults and most children. It’s the second drug to be approved by the regulator to treat the rare disease. The therapy was developed by PTC Therapeutics Inc.
PTCT,
+1.72%
and will be marketed by Genentech, a division of Roche. “We believe Evrysdi, with its favorable clinical profile and oral administration, may offer meaningful benefits for ma…

Click here to view the original article.